Naureen Quibria, Ph.D., is a Vice President, Senior Equity Research Analyst at Maxim Group covering the biotechnology sector, focused primarily on oncology. Dr. Quibria joined Maxim Group as a Senior Research Associate in 2018. Prior to that, she served in various consulting roles, including as Business Analyst at Johns Hopkins Technology Ventures. She began her career in equity research at H.C. Wainwright, followed by JMP Securities. She has also served brief stints as an analyst at B. Riley and Noble Capital Markets. Dr. Quibria has conducted research in academic labs at the NIH, Beth Israel Deaconess Medical Center/Harvard Medical School and at UCLA. She received her Ph.D. in Cell Biology and Pathology from Columbia University and holds a Bachelor’s degree in Biology from Bryn Mawr College.
Naureen Quibria, Ph.D.
Vice President, Senior Research Analyst
Biotechnology | Equity Research